Author:
Brown Ruth E.,Stern Sean,Dhanasiri Sujith,Schey Steve
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference25 articles.
1. Cancer Research UK: Multiple myeloma—UK incidence statistics. http://info.cancerresearchuk.org/cancerstats/types/multiplemyeloma/incidence/index.htm (2010). Accessed 19 July 2011
2. Scott, L.J., Lyseng-Williamson, K.A.: Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs 71, 625–649 (2011)
3. Schey, S., Higginson, I.: Cost-effectiveness of lenalidomide in multiple myeloma. Expert Rev. Pharmacoecon. Outcomes Res. 10, 229–238 (2010)
4. Drayson, M.T., Augustson, B.M., Begum, G., et al.: Survival from relapse and the influence of therapy (Abstract PO-665). Haematologica 92, 173 (2007)
5. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., et al.: Improved survival in multiple myeloma and the impact of novel therapies. Blood 111, 2516–2520 (2008)
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献